Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant

NCT: NCT04380311 · COMPLETED

NCT IDNCT04380311
StatusCOMPLETED
Start Date2020-05-01
Completion2025-04-30
SponsorUniversity of Utah (OTHER)
First posted
Last updated

Brief Summary

Immunosuppressive therapy is required to prevent organ rejection, however, dosing of immunosuppressive agents is complicated by patient-specific differences impacting the body's absorption and elimination of these agents. The goal of this research proposal is to clinically validate an innovative precision medicine strategy for dosing the immunosuppressant tacrolimus in pediatric heart transplant, which will in turn lead to improvements in long-term transplant survival outcomes. The strategy and techniques used in this project can be extended to improve drug therapy across multiple pediatric diseases requiring chronic therapy.

Frequently Asked Questions

What is Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant?

Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant is a clinical trial registered under NCT04380311. Current status: COMPLETED.

What is the status of NCT04380311?

The current status of NCT04380311 (Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant) is: COMPLETED.

When did Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant start?

Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant started on 2020-05-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.